Stockscreener 앱 받기
1.06
1.92%
0.02
Imunon Inc 주식(IMNN)의 최신 뉴스
IMUNON Converts $1.2 Million of Debt-to-Equity - GlobeNewswire
A debt swap cuts IMUNON’s outstanding debt by about 43%, with no common shares issued. - Stock Titan
A 7,169-share salary award leaves Imunon (IMNN) chair with 103,921 shares held directly. - Stock Titan
Part of the CEO’s salary came as stock: Imunon (IMNN) granted Stacy Lindborg 6,697 shares. - Stock Titan
At $1.41 a share, Imunon (IMNN) granted its medical chief 4,390 shares in place of part of his cash salary. - Stock Titan
Imunon Inc (NASDAQ: IMNN) Share Price, IMNN Stock News, IMNN Share Price & Updates - kalkine.com.au
Imunon (IMNN) chair takes stock instead of cash pay - Stock Titan
Imunon (IMNN) CEO adds 5,504 shares in stock grant - Stock Titan
Imunon (IMNN) pays its chief medical officer in stock - Stock Titan
IMUNON partners with National Cancer Institute to expand IL-12 DNA plasmid beyond ovarian cancer - AllSci
Imunon (IMNN) Partners with NCI on IMNN-001 Immunotherapy Amid V - GuruFocus
IMUNON Enters CRADA with NCI’s CTEP to Advance IMNN-001 in New Cancer Indications and Combinations - Quiver Quantitative
IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001 - Yahoo Finance
Imunon schedules R&D day for Sept. 23 to discuss IL-12 therapy By Investing.com - Investing.com Australia
Imunon schedules R&D day for Sept. 23 to discuss IL-12 therapy - Investing.com Australia
Imunon schedules R&D day for Sept. 23 to discuss IL-12 therapy - Investing.com Canada
Imunon schedules R&D day for Sept. 23 to discuss IL-12 therapy - Investing.com UK
IMUNON Announces Full Agenda and Speaker Lineup Ahead of - GlobeNewswire
Imunon schedules R&D day for Sept. 23 to discuss IL-12 therapy - Investing.com Nigeria
Imunon (IMNN) Slips 2.5% to $1.54, Approaching Critical Support at $1.46Stock Analysis - siam.in
Imunon (IMNN) Slips 2.5% to $1.56 as Range-Bound Trading Keeps Key Levels in FocusCharm Flow - siam.in
Imunon Inc (IMNN) Insider Sell: General Counsel and Corp Sec Susan Eylward Sells 2,525 Shares - GuruFocus
Insider at Imunon (NASDAQ: IMNN) logs new stock trade - Stock Titan
Imunon (IMNN) insider reports new stock trade - Stock Titan
Imunon (IMNN) counsel takes salary in stock, then sells the same number of shares days later - Stock Titan
Imunon to host R&D day on phase 3 ovarian cancer trial - Investing.com Canada
Imunon to host R&D day on phase 3 ovarian cancer trial - Investing.com India
Imunon to host R&D day on Sept. 23 for ovarian cancer therapy - Investing.com India
Imunon to host R&D day on phase 3 ovarian cancer trial - Investing.com UK
Imunon to host R&D day on Sept. 23 for ovarian cancer therapy - Investing.com UK
Imunon to host R&D day on phase 3 ovarian cancer trial - Investing.com
Imunon (IMNN) Financial Update: EPS Prints Above Forecast on the Day; The Stock Ends Down 3.05% in the Current UpdateGross Profit Margin - dars.gov.et
Imunon (IMNN) Q2 2026 Results: The Available Earnings Metric Delivers a Beat on the Day; After Earnings: The Stock Records a 3.80% Increase in the Current UpdateQuarterly Profit Report - vinanet.vn
Imunon (IMNN) Q2 2026 Results: The Available Earnings Metric Delivers a Beat on the Day; After Earnings: The Stock Records a 3.80% Increase in the Current UpdateGuidance vs Actual - dars.gov.et
Imunon Earnings Call Highlights Survival Gains, Cash Needs - TipRanks
Imunon (IMNN) Q2 2026 Filing Snapshot: The Bottom-Line Figure Outpaces Its Comparison in the Latest Session; Stock Move: Shares Move 1.25% Lower on the DayEarnings Revision Upgrade - vinanet.vn
Imunon (IMNN) General Counsel and Corp Sec Susan Eylward Sells 2,449 Shares - GuruFocus
Imunon (IMNN) CEO takes 6,615 shares instead of cash pay - Stock Titan
Imunon (IMNN) pays CMO with 3,516-share stock grant - Stock Titan
Imunon (IMNN) pays executive chair with 7,147 shares - Stock Titan
Imunon (IMNN) counsel gets stock in lieu of pay, then sells 2,449 shares - Stock Titan
Imunon (IMNN) Q2 2026 Earnings: Narrower-Than-Expected Loss Drives 4.43% BounceProduct Revenue Analysis - vinanet.vn
Imunon Inc. (IMNN) Advances 4.43% as Biotech Stock Tests Key Resistance at $1.73Fair Value Gap - dars.gov.et
Imunon Inc. (IMNN) Advances 4.43% as Biotech Stock Tests Key Resistance at $1.73Gamma Exposure - vinanet.vn
Imunon Inc. (IMNN) Advances 4.43% as Biotech Stock Tests Key Resistance at $1.73Sector Neutral Pair - careplusvn.com
Imunon Inc. (IMNN) Advances 4.43% as Biotech Stock Tests Key Resistance at $1.73Triple MA Cross - dars.gov.et
Armistice Capital (IMNN) discloses 9.99% Imunon stake via Master Fund - Stock Titan
IMUNON to Hold First Quarter 2025 Financial Results and Business Update Conference Call on Monday, May 12, 2025 - kalkine.ca
Earnings call transcript: Imunon beats Q2 2026 EPS forecast as shares stay weak - Investing.com UK
Maxim Group Maintains Imunon(IMNN.US) With Buy Rating, Maintains Target Price $10 - Moomoo
1.35%
자본화:
|
볼륨(24시간):